Abstract-Using a repeated acquisition procedure in a 3-panel runway apparatus, the effect of WEB 1881 FU on impairment of working memory produced either by scopolamine or by cerebral ischemia was investigated in rats and compared with those of aniracetam and Ca hopantenate.
Recent neurochemical studies on patients with Alzheimer's disease and senile dementia of the Alzheimer type have demonstrated marked reductions in the activity of choline acetyltransferase, the enzyme that synthe sizes acetylcholine, in the cerebral cortex and hippocampus (1-3). This suggests an im pairment of the cholinergic neurotransmission, which may lead to memory deficits in these pathological states. The administration of scopolamine, a muscarinic acetylcholine receptor antagonist, results in impairment of learning and memory in humans (4-6) and animals (7) (8) (9) (10) (11) . Neurons in the central nervous system are also vulnerable to isch emia. After cardiac arrest, some patients shows amnesia characterized in part by a reduced ability to learn new and variable in formation (12, 13) . Rats subjected to cerebral ischemia by 4-vessel occlusion (14) exhibit memory deficits (15) (16) (17) that are accom panied with central cholinergic dysfunction (18) .
WEB 1881 FU (4-aminomethyl-1-benzyl pyrrolidin-2-one-fumarate) has an agonistic action on M, -muscarinic acetylcholine recep tors in the rat brain (19) . It is reported that WEB 1881 FU antagonizes the scopolamine induced loss of retention of the passive avoidance response in mice (20) . Further more, WEB 1881 FU exerts a cytoprotective influence, reducing hypoxic lethality in mice, and decreasing the extent of ATP and phos phocreatine depletion in the rabbit brain fol lowing cerebral ischemia (20). These findings suggest that WEB 1881 FU has a beneficial effect on memory deficits in animal models of dementia.
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In this study, we focused on working memory (21-23). We investigated the effect of WEB 1881 FU on working memory de ficits induced by intraperitoneal scopolamine and cerebral ischemia. These results were compared with two other drugs: another pyrrolidinone derivative, aniracetam; and Ca hopantenate.
Both have been shown to improve experimentally induced amnesia (24) (25) (26) and loss of cognition in some pa tients with senile dementia or cerebrovascular disorders (27, 28).
Materials and Methods
Subjects: Eight to ten-week old male rats of the Wistar strain (SLC) were used in a 3 panel runway task. Initially, their free feeding weights were 230-250 g, but they were maintained at approximately 80% of this level prior to the experiment. The rats were housed in groups of four per cage under a constant temperature (23±2°C) on a 12 hr light-dark cycle (light period: 07:00-19:00) with water freely available.
Apparatus: Working memory was assessed by using a repeated acquisition procedure in a 3-panel runway apparatus (29, 30) . In brief, this apparatus (175 x 36 x 25 cm) is composed of a start box, a goal box, and four consecutive intervening choice points. Each choice point consists of a gate with three panels (12x25 cm). The rats are prohibited from passing through two of the three panels in the gate by front stoppers and prohibited from returning to the start box or a previous choice point by rear stoppers affixed to each of the panels in all gates. When rats reach the goal box, they get two food pellets (about 50 mg, Muromachi Kikai) as a positive reinforcement.
Acquisition training: Initially, all front stop pers were removed so that a rat could pass through any one of the three panel-gates at each choice point. The rats were made to run the task repeatedly until the time elapsed from leaving the start box to reaching the goal box (latency) fell to consistently below 20 sec. Once rats reached this state they were used in six consecutive trials (one session) per day with the front stopper of only one of the three panel-gates (the correct panel-gate) at each choice point removed. Each trial was performed at 2-min intervals, and water was freely available between trials in the home cage. The locations of the correct panel gates were held constant within a session, but were changed from one session to the next (working memory). Twelve patterns of correct panel-gate locations were used in this experiment, as described previously (29, 30). The number of times an animal pushed an incorrect panel-gate and the time required for the animal to obtain food pellets were re corded for each rat on every trial of a session. Rats were used for the experiment if they achieved a criterion of less than 12 errors summed across six trials of a session for each of three consecutive sessions.
Scopolamine administration: Scopolamine in a dose of 0.56 mg/kg was administered intraperitoneally to rats that met the criterion. The runway test was performed 20 min after the scopolamine injection. WEB 1881 FU, aniracetam, and Ca hopantenate were ad ministered per os 40 min before scopolamine administration.
Production of ischemia: Cerebral ischemia was induced by the multi-stage method described by Pulsinelli and Brierley (14) . The rats were anesthetized with sodium pen tobarbital (35 mg/kg, i.p.), and the vertebral arteries were cauterized bilaterally with a bipolar coagulator (Mizuho Ika, MICRO-ID). Threads were then placed around the common carotid arteries but the carotid blood flow was not interrupted. The next day, rats that behaved normally were used in the final phase of ischemia production. After a runway trial, each rat was restrained in the supine position, and the common carotid arteries were exposed by pulling the threads and were occluded with clips. Rats with vertebral artery cauterization and the carotid artery occlusion lost the righting reflex during the period of ischemia and were assigned to the ischemic group. Control rats had their vertebral arteries cauterized, but their carotid arteries were not occluded. The runway test was performed 24 hr after blood flow recirculation. WEB 1881 FU and aniracetam were administered per os immediately after recirculation and again 1 hr before the runway task.
Drugs: The drugs used in this study were WEB 1881 FU (4-aminomethyl-1-benzyl pyrrolidin-2-one-fumarate; Nippon Boehrin ger Ingelheim), aniracetam (Nippon Roche), Ca hopantenate (Tanabe) and (-)scopola mine hydrobromide (Sigma). Aniracetam was suspended in 1 % carboxymethylcellulose solution, and other drugs were dissolved in distilled water. The doses for drugs were ex pressed in terms of the salt, except for anirace tam (calculated as the base). Drugs were ad ministered in a volume of 0.1 ml per 100 g body weight.
Data analysis: The number of errors and latency in the first trial were presented separa tely and summed from the second to sixth trial of a session. The significant difference between groups was determined using a one way analysis of variance (ANOVA) followed by Dunnett's test when F ratios reached significance (P<0.05). 
Results
In the 3-panel runway task, the random performance level is 4 errors per trial and 24 errors per session. With repetition of training, the number of errors made from the second to the sixth trial was markedly decreased, while errors in the first trial remained constant at approximately four (Fig. 1) . Almost 20 train ing sessions were required for rats to achieve a criterion of less than 12 errors summed across six trials of a session. Latency was also reduced with repeated sessions and stabi lized on and after the 10th session.
Intraperitoneal injection of 0.56 mg/kg of scopolamine significantly increased errors in the 3-panel runway task [F=49.36, df=1.14], without affecting the number of errors made in the first trial (Fig. 2 and Table 1 ). Scopola mine prolonged the latency both in the first trial [F=6.47, df=1,14] and from the second to sixth trial [F=19.46, df=1,14] . WEB 1881 FU at doses of 10-32 mg/kg caused a dose related reduction in the increase of errors ex pected in the scopolamine-treated rats [F= 4.18, df=3,28] . WEB 1881 FU had no effect on the increase in latency. As shown in Table  1 , the increase of errors induced by 0.56 mg/ kg of scopolamine was also significantly re duced by aniracetam at 10-100 mg/kg [F= 3.10, df=3,28] as well as Ca hopantenate at 100 and 560 mg/kg [F=8.90, df=2,21 ] . How ever, the prolonged latency in the scopola mine-injected rats was unaffected by these doses of aniracetam or Ca hopantenate.
The five-minute period of cerebral ischemia led to a significant increase in the number of errors in the 3-panel runway task [F=87.47, df=1,10], without affecting errors made in the first trial ( Fig. 3 and Table 2 ). Ischemia prolonged the latency in the first trial [F= 8.81, df=1,10] and from the second to sixth trial [F=74.58, df=1,10]. The administration of 32 and 56 mg/kg of WEB 1881 FU im mediately after blood flow recirculation and then again 1 hr before the test session held the next day significantly reduced the increase in errors that would normally be expected after 5 min of ischemia [F=16.42, df=2,15] . Treatment with these doses of WEB 1881 FU failed to decrease the expected increase in latency. As shown in Table 2 , aniracetam at doses of 32 and 100 mg/kg also caused a significant reduction in the increase of errors induced by 5 min of ischemia [F=7.81, df= 2,15]. Aniracetam at 100 mg/kg decreased the number of errors in the first trial [F=5.44, df=2,15] . A significant reduction of the pro longed latency was seen when rats were treated with 32 mg/kg of aniracetam [F= 9.30, df=2,15] . 
Discussion
There is much evidence that central cho linergic function plays a crucial role in learn ing and memory. For instance, a muscarinic receptor agonist such as oxotremorine or arecoline, and the acetylcholinesterase inhibi tor physostigmine facilitate learning and memory in humans (6, 31) and animals (32). Conversely, scopolamine, a muscarinic an tagonist, has been shown to produce amnesic effects in humans (4-6) and in mice and rats subjected to a passive avoidance test (7) or a radial maze task (8, 11). Similarly, scopola mine causes a disruption of working memory, as indicated by an increase in errors in the 3 panel runway task (29, 30). Our study clearly showed that WEB 1881 FU reversed impairment of working memory induced by scopolamine. This result is con sistent with the fact that WEB 1881 FU an tagonizes scopolamine-induced amnesia in the passive avoidance task in mice (20) . Muscarinic agonists such as oxotremorine and arecoline have been found to block the amnesic effects of scopolamine (33). Kitamura et al. (19) and Ca hopan tenate also antagonized scopolamine-induced impairment of working memory in the runway task. Aniracetam has been found to reverse amnesia in passive avoidance tasks and the decrease in acetylcholine level in the hippo campus produced by scopolamine in rats (24, 25) . Ca hopantenate, which consists of r aminobutyric acid (GABA) and pantoyl moie ties, binds GABA receptors, causing enhance ment of acetylcholine synthesis and release in cholinergic terminals in the cerebral cortex and hippocampus (37, 38) . This suggests that some stimulant action of aniracetam or Ca hopantenate on the central cholinergic system may play a role in the improvement of memo ry deficits produced by scopolamine.
The central nervous system is one of the systems most vulnerable to ischemia. Rats subjected to cerebral ischemia by 4-vessel occlusion (14) exhibit memory deficits, as assessed in passive avoidance tasks (17) and 8-arm radial mazes (15, 16). In our experi ment, impairment of working memory in the 3-panel runway task was successfully pro duced in rats by a 5-min period of cerebral ischemia. WEB 1881 FU as well as aniracetam administered immediately after recirculation and again before a test session conducted 24 hr after ischemia, ameliorated the ischemia induced amnesia. Aniracetam has also been shown to protect against the disruption of memory in an active avoidance task induced in mice by exposure to CO2 (24). However, the mechanisms underlying the activity of aniracetam remain unresolved. In our previous study (30, 39) , cholinesterase inhibitors such as physostigmine, tetrahydroaminoacridine, and amiridin reversed amnesia in the runway task in ischemic models. Yamazaki et al. (17) have reported that physostigmine reverses the ischemia-induced amnesia in the passive avoidance task when it was administered only once before the retention test conducted 24 hr after the ischemia. Pretreatment with physostigmine also protects against the lethal effect of hypoxia in mice (40, 41) . Furthermore, the cholinergic dysfunction, i.e., a significant decrease in acetylcholine and a marked increase in choline, has been noted in the brain of rats with ischemia (18). These findings suggest that the agonistic ac tion of WEB 1881 FU on central M, -mus carinic receptors may be related to the amel ioration of memory deficits induced by cerebral ischemia, although it is not clear which of the effects of two administrations plays a more important role. Cerebral ischemia also causes a marked reduction of brain ATP and phosphocreatine levels in rats (42) and gerbils (43). A recent biochemical study (20) has shown that pretreatment with WEB 1881 FU for 7 days diminishes the breakdown of ATP and phosphocreatine concentrations in the rabbit brain following cerebral ischemia. Therefore, it is conceivable that the memory deficit reversal produced by WEB 1881 FU may result from protection of the brain from the energy failure induced by cerebral isch emia. This is predominantly attributable to the effect of WEB 1881 FU administered im mediately after recirculation, because the high-energy phosphates are rapidly restored to normal levels during the early postischemic period (42, 43) .
We conclude that WEB 1881 FU reverses scopolamine-induced amnesia through its agonistic action on central M,-muscarinic acetylcholine receptors. Both the cholinergic activating action of WEB 1881 FU and its beneficial effect on energy metabolism may play a role in the amelioration of memory deficits in the ischemic model.
